For the treatment of diabetes, a meta-analysis based on 35 randomized controlled trials showed that sodium-glucose co-transport 2 (SGLT2) inhibitors significantly reduced the incidence of AF compared to placebo (45). This evidence concerns the gene SLC5A2 and diabetes mellitus.